Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Current Deferred Revenue (2023 - 2025)

Coya Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $916712.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 59.96% year-over-year to $916712.0; the TTM value through Sep 2025 reached $916712.0, up 59.96%, while the annual FY2024 figure was $848286.0, 8.11% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $916712.0 at Coya Therapeutics, up from $731075.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $939035.0 in Q2 2024 and bottomed at $573089.0 in Q3 2024.
  • The 3-year median for Current Deferred Revenue is $844850.0 (2024), against an average of $807798.6.
  • The largest YoY upside for Current Deferred Revenue was 59.96% in 2025 against a maximum downside of 22.15% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $923109.0 in 2023, then dropped by 8.11% to $848286.0 in 2024, then grew by 8.07% to $916712.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Current Deferred Revenue are $916712.0 (Q3 2025), $731075.0 (Q2 2025), and $841414.0 (Q1 2025).